Arcus Biosciences, Inc. (RCUS) Operating income 2016–2025
Arcus Biosciences, Inc. (RCUS) annual operating income history from SEC filings — each fiscal year as reported.
-$386.0MFY2025 · since FY2016: -$18.2M → -$386.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$386.0M | -17.0% |
| FY2024 | -$330.0M | +2.9% |
| FY2023 | -$340.0M | -21.4% |
| FY2022 | -$280.0M | -618.5% |
| FY2021 | $54.0M | +143.5% |
| FY2020 | -$124.0M | -39.8% |
| FY2019 | -$88.7M | -61.7% |
| FY2018 | -$54.9M | -2.7% |
| FY2017 | -$53.4M | -193.9% |
| FY2016 | -$18.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RCUS financial trends
RCUS RevenueRCUS Net incomeRCUS Net marginRCUS Gross profitRCUS Gross marginRCUS Operating marginRCUS Operating cash flowRCUS Free cash flowRCUS Capital expendituresRCUS Return on equityRCUS Stock buybacksRCUS Dividends paidRCUS Total assetsRCUS Total liabilitiesRCUS Shareholders’ equityRCUS overview →